BNS vs ITUB

The Bank of Nova Scotia (BNS) exhibits a weak financial health profile with a Piotroski F-Score of 2/9, signaling significant concerns in profitability, leverage, and operating efficiency. Despite this, the stock shows strong recent earnings growth (YoY EPS +58.2%) and a robust dividend yield of 4.28%, supported by a high but sustainable payout ratio. Valuation metrics suggest the stock is trading slightly above analyst targets ($74.87 vs. $70.40) and above the Graham Number of $68.74, though below the growth-based intrinsic value of $121.54. Technical indicators are bearish (10/100), and insider sentiment is neutral, reflecting limited conviction despite solid dividend strength.

ITUB presents a contradictory profile: while it maintains a strong ROE of 21.01% and trades near its intrinsic value of $8.96, its deterministic health is severely compromised with a Piotroski F-Score of 2/9. The stock is currently priced at a slight premium to the Graham Number ($8.18) and above the average analyst target price of $8.36. Despite strong historical 1-year price appreciation (+60.3%), the current technical trend is heavily bearish (10/100), suggesting a potential reversal or consolidation phase. The combination of weak fundamental health scores and a high dividend payout ratio offsets the company's dominant market position.